Navigating the Landscape of Antibody Drug Conjugates: Current Trends and Future Research Prospects in Acute Myeloid Leukemia
Frontiers in Bioscience-Elite · 10.03.2026 · 18 (1)
DOI: 10.31083/fbe39323 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Elite, online erschienen am 10.03.2026. Verfasst von Aayushi C Shah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, 380009 Ahmedabad, Gujarat, India. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Immunoconjugates, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute myeloid leukemia (AML) is a hematologic malignancy with a poor prognosis and high relapse rates, especially in high-risk patients and older adults. Conventional treatment modalities confer limited benefit, specifically in relapsed and refractory cases. Antibody drug conjugates (ADCs) are a rapidly advancing treatment option that provides a novel approach to treating AML. The design and mechanistic aspects of ADCs have also been discussed. ADCs combine cytotoxic chemotherapeutic drugs with the specificity of monoclonal antibodies. This review primarily focuses on the current role of ADCs in the treatment of AML, including approved agents such as gemtuzumab ozogamicin, as well as others. Moreover, challenges associated with the use of ADCs have been explored, including resistance mechanisms, drug stability, immunogenicity, and cost. This review also highlights and summarizes various ongoing and completed clinical trials, which may provide insight into this treatment approach. Future advancements in AML treatment, including the use of nanoparticles or nanostructures, have also been discussed. In conclusion, this comprehensive review sheds light on the current and prospective future directions of ADCs in the treatment of AML, highlighting their potential to significantly alter the therapeutic landscape for this cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Pharmacy Practice, L. M. College of Pharmacy, 380009 Ahmedabad, Gujarat, India.
- Department of Product Development, Granules Pharmaceuticals Inc., Chantilly, VA 20151, USA.
- Centre for Research Impact & Outcome, Chitkara College of Pharmacy, Chitkara University, 140401 Rajpura, Punjab, India.
- School of Pharmacy, RK University, 360020 Rajkot, Gujarat, India.
- Department of Industrial Pharmacy, Faculty of Pharmacy, Silpakorn University, 73000 Nakhon Pathom, Thailand.
- Now with Department of Pharmaceutics, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University, 391760 Vadodara, Gujarat, India.
Zitieren
APA
Shah, A. C., Saluja, S. G., Trivedi, J. D., Mehta, S. H., Patel, R., Chorawala, M. R., Dudhat, K., & Prajapati, B. G. (2026). Navigating the Landscape of Antibody Drug Conjugates: Current Trends and Future Research Prospects in Acute Myeloid Leukemia. Frontiers in Bioscience-Elite, 18(1). https://doi.org/10.31083/fbe39323
Vancouver
Shah AC, Saluja SG, Trivedi JD, Mehta SH, Patel R, Chorawala MR, et al. Navigating the Landscape of Antibody Drug Conjugates: Current Trends and Future Research Prospects in Acute Myeloid Leukemia. Frontiers in Bioscience-Elite. 2026;18(1). doi:10.31083/fbe39323
BibTeX
@article{Shah2026,
author = {Shah, Aayushi C and Saluja, Sunayna G and Trivedi, Jeel D and Mehta, Shreeja H and Patel, Rajanikant and Chorawala, Mehul R and Dudhat, Kiran and Prajapati, Bhupendra G},
title = {Navigating the Landscape of Antibody Drug Conjugates: Current Trends and Future Research Prospects in Acute Myeloid Leukemia},
journal = {Frontiers in Bioscience-Elite},
year = {2026},
volume = {18},
number = {1},
doi = {10.31083/fbe39323}
}
EUVIMED